

頭頸部がんの症状を緩和する高度技術 (Abstract 6063)

モバイルセンサーソフトウェアを用いて頭頸部がん症状の重症度を低下させる
Use of mobile and sensor technology lowers symptom severity for people with head and neck cancer

頭頸部がんに対し放射線療法を受けている患者で、モバイルセンサーソフトウェアを用いて症状の遠隔モニタリングを実施されている者は、がんとその治療による症状のいずれもがそれほどひどくないと報告した。と2018 ASCO Annual Meetingで発表された。参加者は、CYCOREと呼ばれるモバイルセンサーソフトウェア（169人）または通常のケアを受ける群（188人）にランダムに割り付けられた。CYCORE群はBluetooth対応の血圧計カフおよび体重計を使用した。放射線治療完遂後、CYCORE群は通常ケア群に比べ、平均全身症状および頭頸部がん特異的症状に関するスコア（それぞれ2.9対3.4および4.2対4.8）が低かった（すなわち良好）であった。

Full Text

A randomized clinical trial of 357 people receiving radiation for head and neck cancer, using mobile and sensor technology to remotely monitor patient symptoms, resulted in less severe symptoms related to both the cancer and its treatment (both general and cancer-related).

Patients who used the technology – which included a Bluetooth-enabled weight scale, Bluetooth-enabled blood pressure cuff, and mobile tablet with a symptom-tracking app that sent information directly to their physician each weekday – had lower symptom severity than participants who had standard weekly visits with their doctors.

In addition, daily remote tracking of patient wellbeing, according to the researchers, enabled physicians to detect concerning symptoms early and respond more rapidly, compared to usual care. These findings will be presented at the upcoming 2018 ASCO Annual Meeting in Chicago.

"Our study generated evidence on how newer technologies can be integrated into cancer care relatively easily and improve patient outcomes without interfering too much in a person's daily life," said lead study author Susan K. Peterson, PhD, professor, Department of Behavioral Science, The University of Texas MD Anderson Cancer Center, Houston. "This study was done during a rather intense period in the patients' care for head and neck cancer. The system helped their physicians to provide valuable support that ultimately resulted in lower symptom severity."

This trial used a technology system called CYCORE (CYber infrastructure for COMparative Effectiveness REsearch), developed collaboratively by four institutions through a grant from the National Cancer Institute.

Participants were randomly assigned to CYCORE (169 people) or usual care (188 people), which consisted of weekly doctor visits. People in the CYCORE group received sensors (blood pressure cuffs and weight scales) that were Bluetooth-enabled. They also got mobile tablets with proprietary Wi-Fi. An in-home wide area network (WAN) hub/router transmitted their sensor readouts, and a mobile app transmitted their symptom data through a back-end cyber-infrastructure to secure firewall-protected computers at MD Anderson to ensure patient information confidentiality.

For the CYCORE group, physicians reviewed data from the app and sensor transmissions remotely each weekday and could intervene in a person's care if necessary. Both CYCORE and usual care participants had weekly in-person doctor visits.

At the start of radiation therapy, study participants completed a 28-item MD Anderson Symptom Inventory survey about their health and common activities of daily living. The survey covered general symptoms that are common in people with cancer, such as pain, fatigue, and nausea, as well as symptoms that are particularly relevant to people with head and neck cancer, such as difficulty swallowing or chewing, skin pain/burning/rash, and problems with tasting food. The participants completed a similar survey at the end of their radiation therapy, usually 6 to 7 weeks later. A final survey was completed 6 to 8 weeks after their radiation therapy ended.

There was no difference in self-reported health severity scores between the CYCORE participants and those who received usual care at the start of the trial. Symptoms severity was scored on a scale of 0 to 10, with zero being no symptom or pain and 10 being the highest level of symptom severity. After completion of radiation therapy, the CYCORE participants had lower (i.e. better) mean scores for general symptoms vs. usual care participants (2.9 vs. 3.4), as well as lower mean scores for symptoms specific to head and neck cancer (4.2 vs. 4.8).

Six to 8 weeks after completion of therapy, CYCORE participants had a mean score of 1.6 vs. 1.9 for usual care participants based on overall health. Both groups had slightly higher severity scores for specific head and neck symptoms (1.7 vs. 2.1).

Most patients (80% or more) adhered to daily monitoring, which was an excellent outcome given the intensity of their treatments, noted Dr. Peterson. Scores reflecting how various symptoms interfered in activities of daily living were about the same in both groups across the entire time of survey reporting.

"This study demonstrates the power of leveraging smart technology to improve the care of people with cancer. These tools helped simplify care for both patients and their care providers by enabling emerging side effects to be identified and addressed quickly and efficiently to ease the burden of treatment. I hope that these or similar technologies will be broadly available to patients soon," said ASCO President Bruce E. Johnson, MD, FASCO.

While the authors were able to recruit people from a wide range of ages, the study population was mostly white, which closely reflected the overall head and neck patient population at the cancer center. The next step for researchers may be to determine how long the benefit of a CYCORE intervention could persist. They also hope to implement the CYCORE intervention in non-academic cancer treatment settings where the majority of cancer patients receive their treatment.

This study received funding from the National Institutes of Health.

ASCO2018特集

[News 01]

ネララピンはT細胞性悪性腫瘍の生存率を改善する

[News 02]

頭頸部がんの症状を緩和する高度技術

[News 03]

乳がんの治療期間を短縮することで心臓における副作用リスクは低下する

[News 04]

がんサバイバーにおける不眠症管理の選択肢

[News 05]

新たな分子標的治療は進行乳がんの増殖を遅らせる

[News 06]

21個の腫瘍遺伝子は乳がんの個別化治療の決定に役立つ

[News 07]

ベンプロリズマブは初回肺がん治療に有効

[News 08]

スタディによりいくつかの新たながんとLynch症候群が関連付けられた

[News 09]

血液検査が早期肺がんを検出できる可能性が示された

[News 10]

進行腎臓がんに対する腎摘出術回避

[News 11]

膀胱がんにおいて術前化学放射線療法は有益である

[News 12]

新たな化学療法レジメンは膀胱がんの生存率を改善する

[News 13]

進行大腸がんに対しては治療が少ない方がよい可能性がある

[News 14]

ここ30年における横紋筋肉腫治療の一番の進歩

[News 15]

エソメプラゾールとアスピリンの併用は食道がんを予防する

[News 16]

進行扁平上皮NSCLCの予後改善